Home
Cellectis
Home
FAQ
Job opportunites
Site map
Contact
Location
Search
Home > Investor Relations

Investor Relations

Company overview:

Incorporated:January 2000
Stock exchange:Alternext by NYSE-Euronext, Paris
Ticker code:ALCLS
ISIN code:FR0010425595
Number of outstanding shares:9,194,926 (as of Mai 10 2008)
Listing date:Feb 7 2007
Activity:Cellectis develops high-precision, high-performance systems for DNA surgery and cell reprogramming.
Alliances:Bayer Biosciences, DuPont Pioneer HiBred, Limagrain Biogemma, Celonic, Frementas, Shire Pharmaceuticals
Legal form:French "Société Anonyme" (SA) with a Board of Directors.
Chief Executive Officer:André Choulika PhD
Corporate HQ and laboratories:Parc Biocitech 102, avenue Gaston Roussel
F-93235 Romainville cedex, France
Number of employees:50 (including 38 R&D staff) as of Mai 1 2006

Cellectis shares

Share priceLink to NYSE-Euronext
Stock exchange Alternext by NYSE Euronext, Paris
Ticker code: ALCLS
ISIN code: FR0010425595
Number of outstanding shares 9,194,926 (as of May 10 2008)
Listing date February 7 2007
CELLECTIS SA
RATIONAL GENOME ENGINEERING

Parc Biocitech 102 avenue Gaston Roussel - F-93235 Romainville Cedex
Tel.: +33 1 41 83 99 00 - Fax: +33 1 41 83 99 03
Last Update 12/11/2008 Legal Notice
Version Française